Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants
Primary Purpose
Infection, Viral, Enterovirus
Status
Withdrawn
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
400 U EV71 vaccine with adjuvant
Sponsored by

About this trial
This is an interventional prevention trial for Infection, Viral, Enterovirus
Eligibility Criteria
Inclusion Criteria:
- Healthy males and females, aged from 6 to 11 months old Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
- Provided legal identification for the sake of recruitment.
- Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed consents.
- Birth weight more than 2500 grams
Exclusion Criteria:
- History of Hand-foot-mouth Disease
- Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
- Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
- Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
- Epilepsy, seizures or convulsions history, or family history of mental illness
- Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
- History of asthma, angioedema, diabetes or malignancy
- History of thyroidectomy or thyroid disease that required medication within the past 12 months
- Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
- Acute illness or acute exacerbation of chronic disease within the past 7 days
- Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
- History of any blood products within 3 months
- Administration of any live attenuated vaccine within 28 days
- Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
- Axillary temperature > 37.0 centigrade before vaccination
- Abnormal laboratory parameters before vaccination
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Sites / Locations
- GuangXi Center for Diseases Control and Prevention
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Group 1: 400U EV71 vaccine without adjuvant
Group 2: 400U EV71 vaccine without adjuvant
Group 3: 400U EV71 vaccine with adjuvant
Arm Description
60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart
60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant
60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant
Outcomes
Primary Outcome Measures
Neutralization antibody geometric mean titer in infants 28 days after immunization with 400U vaccine with or without aluminium hydroxide adjuvant
Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus >= 1:8
Secondary Outcome Measures
The rates and severity of solicited and unsolicited adverse events in infants following immunization as a Measure of Safety and Tolerability
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01812135
Brief Title
Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants
Official Title
A Double-blind and Randomized, Phase II -02 Study With Inactivated EV71 Vaccines in Healthy Infants
Study Type
Interventional
2. Study Status
Record Verification Date
March 2013
Overall Recruitment Status
Withdrawn
Why Stopped
Based on the previous study results, inactivated EV71 vaccine with aluminum adjuvant was elected to be used for the efficacy Phase III study.
Study Start Date
September 2011 (undefined)
Primary Completion Date
November 2011 (Anticipated)
Study Completion Date
December 2011 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sinovac Biotech Co., Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A randomized, double-blind, phase II-02 clinical trial is to evaluate the safety and immunogenicity of an inactivated EV71 vaccine with or without aluminum adjuvant
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection, Viral, Enterovirus
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group 1: 400U EV71 vaccine without adjuvant
Arm Type
Experimental
Arm Description
60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart
Arm Title
Group 2: 400U EV71 vaccine without adjuvant
Arm Type
Experimental
Arm Description
60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant
Arm Title
Group 3: 400U EV71 vaccine with adjuvant
Arm Type
Experimental
Arm Description
60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant
Intervention Type
Biological
Intervention Name(s)
400 U EV71 vaccine with adjuvant
Other Intervention Name(s)
EV71 vaccine
Intervention Description
400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
Primary Outcome Measure Information:
Title
Neutralization antibody geometric mean titer in infants 28 days after immunization with 400U vaccine with or without aluminium hydroxide adjuvant
Description
Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus >= 1:8
Time Frame
2 months
Secondary Outcome Measure Information:
Title
The rates and severity of solicited and unsolicited adverse events in infants following immunization as a Measure of Safety and Tolerability
Time Frame
2 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
11 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy males and females, aged from 6 to 11 months old Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
Provided legal identification for the sake of recruitment.
Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed consents.
Birth weight more than 2500 grams
Exclusion Criteria:
History of Hand-foot-mouth Disease
Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
Epilepsy, seizures or convulsions history, or family history of mental illness
Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
History of asthma, angioedema, diabetes or malignancy
History of thyroidectomy or thyroid disease that required medication within the past 12 months
Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
Acute illness or acute exacerbation of chronic disease within the past 7 days
Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
History of any blood products within 3 months
Administration of any live attenuated vaccine within 28 days
Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
Axillary temperature > 37.0 centigrade before vaccination
Abnormal laboratory parameters before vaccination
Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yan-pin Li, MD
Organizational Affiliation
Guangxi Centers for Disease Control and Prevention
Official's Role
Principal Investigator
Facility Information:
Facility Name
GuangXi Center for Diseases Control and Prevention
City
Nanning
State/Province
Guangxi
Country
China
12. IPD Sharing Statement
Learn more about this trial
Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants
We'll reach out to this number within 24 hrs